The Fenway Institute at Fenway Health is excited to announce an innovative and timely new study exploring the body’s response to COVID-19. Since Fenway Health’s inception, we have been at the forefront of responding to emerging infectious disease. The COVID-19 study is an important example of how we continue that work during this time.
This study is aiming to learn more about COVID-19 and how our bodies respond to and recover from the infection. Eligible study participants include anyone 18 years or older who has tested positive for COVID-19.
“As part of the global response to the AIDS pandemic, The Fenway Institute built up the capacity to conduct cutting edge clinical research as part of the NIH’s HIV Vaccine and HIV Prevention Trials Networks (HVTN and HPTN),” said Dr. Kenneth Mayer, Medical Research Director at Fenway Health and Co-Director of The Fenway Institute.
“This infrastructure is now being repurposed to address the COVID-19 pandemic. HVTN 405 is the first of such studies, which is designed to understand the immune respond to SARS-CoV-2, the virus that causes COVID-19 infection. This study will help inform the development of vaccine trials, which will also be conducted at The Fenway Institute,” he explained.
Study participants will be asked to take part in at least one study visit, with the potential of three additional visits over the course of on year. Participants will be compensated for their time and contributions to this potentially life-saving research.
Your immune system could help researchers end the global pandemic. Please consider joining this study and join the battle against COVID-19.
Ready to sign up? Please click here to take an online screener to see if you may be eligible.
To learn more about this study, please call us at 617.927.6450, email us at [email protected], or text @COVID to 39242.